Permira is selling Australia's I-Med Radiology Network, which recently entered the U.S. by acquiring StatRad, to Hong Kong-based multinational conglomerate Jardine Matheson.
The Bedford, Massachusetts-based company has reportedly been approached about a possible acquisition by competitor Curium Pharma, Bloomberg reported May 22.
Last week hospitals owned by three big health systems filed suit against CVS Health. The trio filed separately, but all accuse the corporation of robbing them of funds they’re owed through the federal 340B drug pricing program.
Quorum Health said the move will allow it to save money through tax exemptions and provide its 11 hospitals with access to the 340B Drug Pricing Program. The health system is majority-owned by Goldentree Asset Management.
The change would represent an imperfect but, in many cases, perfectly appropriate way to oversee the technology without crimping its capabilities. So say three thought leaders who are close watchers of medical ethics and technologies.
The intrusion was caused by the compromised credentials of a Hartford HealthCare employee. Data stolen included full names, Medicaid ID numbers and patient treatment details.
"Pulmonary embolism is fundamentally a cardiovascular disease, where restoration of hemodynamic stability, beyond simple clot removal, is the key determinant of patient recovery,” one researcher explained.
First revealed in March, the incident was confirmed to be months long. NYC Health + Hospitals blamed the intrusion on an unnamed third-party vendor. Stolen data includes medical records, finger and palm prints, and location data from patients and workers alike.
HHS Secretary Robert F. Kennedy Jr. is appointing Stephanie Haridopolos, MD, to carry out some of the functions of the “nation’s doctor," with the SG post empty since Trump took office.
Permira is selling Australia's I-Med Radiology Network, which recently entered the U.S. by acquiring StatRad, to Hong Kong-based multinational conglomerate Jardine Matheson.
The Bedford, Massachusetts-based company has reportedly been approached about a possible acquisition by competitor Curium Pharma, Bloomberg reported May 22.
